How Does Evenity Compare to Other Osteoporosis Treatments?

Bone loss does not wait, and neither should your treatment, but choosing the right osteoporosis treatments means understanding what each one actually does to your bones. You have probably heard more treatment names than you can keep straight. Bisphosphonates, Prolia, Forteo, and now Evenity. It is a lot. So here is the short answer: Evenity (romosozumab) stands apart from most osteoporosis treatments because it is the only one that both builds new bone and slows bone loss at the same time. Most other treatments do one or the other. That dual action makes it especially useful for patients at the highest risk of fracture.

Here is what that actually means in practice.

What Makes Evenity Different

Most osteoporosis treatments fall into one of 2 categories: they either slow down bone loss or they stimulate new bone growth. Evenity does both.

It works by blocking a protein called sclerostin. Sclerostin normally puts the brakes on bone formation. When romosozumab blocks it, bone-building cells (osteoblasts) become more active. At the same time, the drug mildly reduces the activity of bone-breaking cells (osteoclasts). The result is faster, more significant gains in bone mineral density than you get with most other options.

That dual mechanism is not shared by any other approved osteoporosis medication. It is genuinely a different class of drug.

Evenity vs. Bisphosphonates (Fosamax, Boniva, Reclast, Actonel)

Bisphosphonates are the most commonly prescribed osteoporosis medications. They work by slowing bone resorption. They do not build new bone; they simply preserve what you have.

That is useful for many patients. But for someone who has already fractured a bone or has very low bone density, “preserving what you have” may not be enough. Bisphosphonates are also associated with gastrointestinal side effects, and long-term use carries a small but real risk of atypical femur fractures and osteonecrosis of the jaw.

Evenity, by contrast, actively builds new bone during its 12-month treatment course. Research published by the National Institutes of Health found that romosozumab led to hip bone mineral density gains not seen with bisphosphonate therapy in patients who had previously fractured while on bisphosphonates. For patients who have already tried bisphosphonates and are still fracturing, Evenity represents a meaningful step up.

Evenity vs. Prolia (Denosumab)

Prolia is an anti-resorptive medication given by injection every 6 months. It slows bone breakdown effectively. Many patients do well on it. However, it requires ongoing treatment. If you stop Prolia without transitioning to another medication, bone loss can rebound quickly.

Evenity is prescribed for just 12 months total. After completing treatment, patients typically transition to an anti-resorptive drug like Prolia or a bisphosphonate to preserve the gains made. Evenity builds the bone; the follow-up medication maintains it.

The 2 drugs are not head-to-head competitors so much as they are sequential partners. Evenity is a starting point for patients at very high fracture risk. Prolia often becomes the maintenance option afterward.

Evenity vs. Forteo and Tymlos (Teriparatide and Abaloparatide)

Forteo and Tymlos are both anabolic drugs, meaning they stimulate bone formation. They are daily injections, often used for 18 to 24 months. Both reduce vertebral fracture risk significantly.

The key distinction is in the mechanism. Forteo and Tymlos stimulate bone remodeling, which includes some increase in bone resorption alongside formation. Evenity builds bone while simultaneously reducing resorption. That combination produces a stronger net gain in bone mineral density in a shorter window.

Clinical data from the ARCH trial showed that romosozumab followed by alendronate reduced the risk of vertebral fractures by 48% compared to alendronate alone. It also reduced clinical fractures by 27% compared to alendronate over 24 months. That is a meaningful difference.

Another practical consideration: Forteo and Tymlos require daily self-injection. Evenity is given monthly in a clinical setting, which works better for patients who prefer a supervised, structured schedule.

Who Is Evenity Best Suited For?

Evenity is FDA-approved for postmenopausal women at high risk of fracture. That generally includes:

• Women with a T-score of -2.5 or lower
• Those with a history of fragility fractures (fractures from minor falls or everyday activity)
• Patients who have not responded adequately to other treatments
• Those who cannot tolerate oral bisphosphonates due to GI issues

Evenity is not appropriate for everyone. It carries a boxed warning for cardiovascular risk. Anyone with a history of heart attack or stroke should not use it. Your provider will weigh that risk carefully before recommending it.

The Role of Infusion Specialists

Evenity is administered as 2 subcutaneous injections given once monthly for 12 months, always by a healthcare provider. That is where we fit in. Infusion Specialists manages the administration of specialty medications and monitors your progress throughout treatment of Osteoporosis and other conditions.

The goal is to make the process as smooth as possible, so you can focus on getting stronger rather than navigating logistics.

Ready to Talk About Your Options?

If you or someone you love is managing severe osteoporosis and weighing treatment options, the team at Infusion Specialists is here to help. Contact us to ask questions, learn more about what to expect, or get started with a referral. You do not have to figure this out alone.